Since the second half of the 20 th century the incidence of tuberculosis has been declining in Poland. Despite this, current epidemiological data still support the need for the continued mass BCG vaccination in Poland in the near future. Apart from the protection against severe hematogenous forms of tuberculosis, vaccination lowers the risk of infection with Mycobacterium tuberculosis. Primary and acquired immunodeficiency, including immunity disorders associated with an ongoing treatment, are contraindications to BCG vaccination. The most common adverse effects following BCG vaccination are reactions at the site of injection and in regional lymph nodes, which usually does not require treatment. Methods of tuberculosis prevention, particularly recommended in low-incidence countries, include: diagnostic investigations of patients who had contacts with pulmonary tuberculosis as well as an active detection and treatment of latent Mycobacterium tuberculosis infection. Latent tuberculosis infection can be identified on the basis of positive results of the tuberculin skin test or interferon-gamma release assays after the active disease has been ruled out. This condition does require prophylactic treatment.
Since the 1950s, the incidence of tuberculosis has been systematically declining in Poland [1] . In 2010, Poland has become a low-incidence country, where the role of tuberculosis prevention is particularly emphasized [2] .
Basic tuberculosis prevention methods include the following:
• BCG vaccination; • detection of latent tuberculosis infection (prophylactic and preventive treatment in risk groups); • active tuberculosis detection in risk groups; • isolation and immediate treatment of infectious patients [2] . This article presents current guidelines concerning BCG vaccination, tuberculosis contact investigation as well as the diagnostic workup and preventive treatment of latent tuberculosis infection.
BCG vaccination
The BCG vaccine contains the attenuated live strain of bovine tuberculosis bacillus (M. bovis). The vaccine has been named after its creators: Albert Calmette and Camille Guerin: M. bovis BCG (Bacillus Calmette-Guerin). Its implementation in the 1920s significantly decreased the incidence of severe hematogenous forms of tuberculosis (miliary tuberculosis and tuberculous meningitis) among infants and young children and reduced mortality associated with this disease [2, 3] . Current data indicate that BCG vaccination also lowers the risk of infection with Mycobacterium tuberculosis by approximately 19% and decreases the risk of progression to active tuberculosis by 71% [4] [5] [6] [7] .
According to the recommendations of the International Union Against Tuberculosis and Lung Diseases (IUATLD) [8] , mass BCG vaccination is recommended in countries with sputum smear-positive pulmonary tuberculosis incidence equal to or greater than 5/100,000 in the past 3 years. Despite a continuously improving situation in Poland, this value reached 7.3-7.1-6.8/100,000/year in the years 2014-2016, respectively [1] .
As all other compulsory vaccination programs, BCG vaccination is mandatory, and any refusal should be reported in writing to the local public health inspector [9] .
Contraindications to BCG vaccination (apart from those generally acknowledged for all vaccines) include the following [10, 11]:
• body mass ≤ 2,000 g, • congenital impairment of cell-mediated immunity or its suspicion, • impairment of cell-mediated immunity in the family until their exclusion in the child, • HIV infection (children of HIV-positive mothers can be vaccinated after HIV infection in the child has been ruled out), • immunosuppression (e.g. steroid therapy, cytostatic drugs, treatment with TNF-alpha antagonists, radiotherapy), • immunosuppressive treatment of the mother in the third trimester of gestation (vaccination should be postponed; in the case of treatment with TNF-alpha antagonists in the third trimester of pregnancy, the concentrations of the above mentioned drugs in the blood of infants have been detected up to the 6 th , or even 12 th month of life) [12, 13] 
Normal local reaction after BCG vaccination
A natural, local reaction after BCG vaccination involves redness appearing 2-3 weeks after the injection. Several weeks later, a nodule evolving to a pustule develops. It then ruptures to form a slight ulceration, and then crusts. The crust usually falls off after 8-10 weeks, leaving a slight scar measuring 6-8 mm in diameter [10] . The diameter of the pustule and ulceration should not exceed 10 mm in children vaccinated in the first year of life, and 20 mm in children vaccinated at an older age. A greater ulceration is considered a vaccine adverse event (VAE). The total healing time does not usually exceed 3 months [10]. The skin reaction at the site of BCG injection is usually accompanied by slightly enlarged (to 15 mm in diameter) lymph nodes (axillary, supraclavicular, subclavicular) [10].
Adverse events after BCG vaccination
The risk of VAEs is associated with the dosage, substrain (reactogenicity) of bacteria included in the vaccine and the manner of administration [5] . Differences between individual substrains have appeared as a result of passages in different laboratory settings over many years [19] . The Danish The symptoms can develop within a week to even a dozen weeks after vaccination. In lymphadenopathy without accompanying purulent reactions, observation is sufficient. In suppurative lymphadenitis, the following are recommended: -slight reactions: observation only, -signs suggesting a fistula (fluctuation of the purulent content, skin thinning over the affected node): aspiration puncture and collection of the material for bacteriological examination for the concomitant infection. The puncture shortens the duration of the reaction, lowers the risk of spontaneous perforation and formation of a disfiguring scar [22] [23] [24] . Lymph node removal is not recommended as it is the last resort in persisting purulent inflammation.
Distant reactions
Distant reactions include:
• skin changes (ulcerating, lichenoid, nodular) beyond the injection site, erythema nodosum, • iritis, conjunctivitis, optic neuritis, • osteomyelitis [5] .
Osteomyelitis
In Poland, it usually develops in individuals with cell-mediated immunity impairment. However, this complication is also observed in immunocompetent individuals [25] in countries where more reactogenic BCG substrains (Pasteur and Danish) are used [5] .
It manifests as a bone defect, soft tissue edema, pain, restricted mobility and sparing of the affected area [25] .
If this complication develops, the patient must be diagnosed with immunodeficiency (cell-mediated immunity disorders, severe immunodeficiency, HIV infection), and the etiology of infection must be confirmed (bacteriological tests for M. bovis BCG in the referential tuberculosis laboratory). The treatment consists in combined anti-tuberculosis therapy without pyrazinamide (PZA) as M. bovis BCG is naturally resistant to this drug. Certain cases do require surgical intervention.
If multiple changes are observed, the patient should be diagnosed with systemic BCG dissemination.
Disseminated and systemic tuberculosis (BCG-itis) develops very rarely, usually in persons with a more severe impairment of cell-mediated immunity [26] [27] [28] .
BCG-itis is manifested by general signs: fever or subfebrile temperature, failure to thrive, and distant tuberculosis changes beyond the injection site (in the skin, lymph nodes, lungs, liver, spleen, bones and soft tissues) [28] . When BCG-itis is suspected or there are distant reactions after BCG vaccination, the patient requires urgent diagnosis and treatment in a specialist center with diagnostic facilities enabling the identification of immunodeficiency (cell-mediated immunity deficits, severe complex immunodeficiency) and confirmation of the etiology of infection. The treatment involves first-line antituberculous agents excluding PZA: isoniazid (INH), rifampicin (RMP) and ethambutol (EMB). When the suspicion of BCG-itis is justified, treatment should be implemented instantaneously before bacteriological confirmation arrives. The prognosis is grave.
General guidelines for VAEs after BCG vaccination
Obligatory procedures to be performed in all children with a VAE after BCG vaccination:
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• collect the family history of immunodeficiency, • collect the history concerning the occurrence of the following symptoms: subfebrile temperature, appetite disorders, failure to thrive, apathy • conduct a careful physical examination with particular attention paid to: skin reactions, peripheral lymph nodes, percussion signs over the lung fields as well as the size of the liver and spleen, • assess complete blood count (with the emphasis on the absolute lymphocyte count), • report VAEs to the local public health inspector.
Local and nodal reactions after BCG vaccination are not contraindications to the continuation of the remaining immunization programs in accordance with the Preventive Vaccination Program.
Diagnostic workup for latent tuberculosis infection (LTBI)
Latent tuberculosis infection can be identified basing on positive immunological tests: the tuberculin skin test and/or IGRA in the absence of clinical and radiological signs of tuberculosis.
As stated in the WHO guidelines from 2015, systematic screening for and proper treatment of LTBI in countries with annual incidence of tuberculosis < 100/100,000 and with a good economic status should be conducted in:
• HIV-infected individuals, • children and adults who have come into contact with a person with pulmonary tuberculosis, • patients with planned treatment with TNF-alpha antagonists, • organ or bone marrow transplant recipients, • patients on dialysis, • patients with silicosis. Screening for LTBI should also be considered in: • immigrants or refugees from countries with widespread tuberculosis, • drug addicts, • the homeless, • prisoners, • health care personnel [29] .
The quoted WHO guidelines do not indicate the need for LTBI screening before the implementation of long-term immunosuppressive treatment (except for organ and bone marrow transplant recipients and candidates for TNF-alpha antagonist therapy). However, the opinion of the Some authors suggest that both steroid therapy and other immunosuppressants increase the risk of developing tuberculosis, but to a lower degree than TNF-alpha antagonists [32, 33] .
It therefore seems justified to screen for LTBI before the implementation of any prolonged immunosuppressive treatment in children and especially in the following situations:
• in patients at a high risk of tuberculosis infection (positive family history of tuberculosis, origin from a country with high incidence of tuberculosis), • if treatment with TNF-alpha antagonists is planned as the next step of therapy (this is because the TST and IGRA do not yield reliable outcomes after implementation of steroids or other immunomodulatory drugs). Before performing diagnostic tests for latent M. tuberculosis infection, typical signs of active tuberculosis must be ruled out (persisting cough, subfebrile temperature, weight loss or failure to thrive, night sweats, weakness, chest pain, hemoptysis). When active tuberculosis is suspected, the diagnostic process should be extended: a plain chest radiography and bacteriological tests for tuberculosis should be ordered.
In order to identify M. tuberculosis infection in accordance with the WHO guidelines, the tuberculin skin test or IGRA have to be performed.
According to the guidelines of the Tuberculosis Network (TBnet), both tests should be used simultaneously in children before the transplantation of solid organs and bone marrow and prior to treatment with TNF-alpha antagonists [34, 35] .
Furthermore, due to a higher diagnostic sensitivity with both tests, their simultaneous application should be considered in the remaining patients with a high risk of developing tuberculosis (Table 1) .
In children with a low risk of TB disease, TST or IGRA may be used.
When any of these tests are positive, a plain chest radiography should be performed. The presence of abnormalities compatible with tuberculosis forces an extended diagnostic process (including bacteriological tests for tuberculosis). There are no studies that would show the superiority of any of the 6-or 9-month INH therapy; WHO indicates equivalence of both regimens. The American Academy of Pediatrics suggests 9 months [31] , while the 6-month regimen is recommended in Poland.
The dosage in LTBI is consistent with that used in the treatment of active tuberculosis:
• INH in children: 10 mg/kg (7-15 mg/kg), in adults: 5 mg/kg (a maximum daily dose 300 mg), • RMP in children: 10 mg/kg (10-20 mg/kg), in adults: 10 mg/kg (a maximum daily dose 600 mg) [14, 29] . It must be remembered that only INH is registered for preventive treatment in Poland. Parental consent must be acquired for off-label use of RMP.
Prior to the initiation of treatment, baseline values of transaminases and bilirubin should be determined in:
• patients with an earlier or current liver disease, • patients abusing alcohol, • HIV-infected individuals, • pregnant women or in the first 3 months after childbirth. If baseline transaminase values are slightly increased, they must be systematically monitored during the treatment.
The remaining patients treated for LTBI should be regularly examined by a physician (clinical assessment, motivation to continue treatment, adverse effects monitoring). Patients and their parents should be familiar with potential adverse effects in order to report to the doctor immediately if they develop. The most common adverse effects are as follows: loss of appetite, nausea, vomiting, abdominal pain, fatigue, weakness, dark urine, pale stool and jaundice. If these symptoms develop and medical consultation is not possible, the treatment should be stopped.
Tuberculosis contact investigation
In accordance with the Act of 5 December 2008 on Prevention and Treatment of Infections and Infectious Diseases in Humans, individuals who come into contact with a tuberculosis patient should be under epidemiological surveillance, should undergo clinical examination and diagnostic tests or if needed, a preventive pharmacological treatment [9] .
Contact with tuberculosis patient (necessitating diagnostic measures) is defined as: -staying in one room with a sputum smear-positive individual (acid fast bacilli+, AFB+) for a total of 8 hours for up to 3 months before diagnosis; -staying with a sputum smear-negative (AFB-) but sputum culture-positive individual for cumulative 40 hours for up to a month before diagnosis; -a brief intensive face-to-face contact (e.g. during a laryngological examination or dental treatment) with a patient with pulmonary tuberculosis [33] . NOTE: The presence of a cavity on chest radiography or a cough increases the degree of infectiousness.
A tuberculosis patient stops being infectious approximately 2 weeks after the treatment implementation (when bacterial sensitivity to the treatment is presumed or confirmed, and the clinical improvement is noted).
Diagnostic tests should be conducted in individuals exposed to an index case of bacteriologically confirmed pulmonary tuberculosis (with positive sputum cultures or smears when the molecular tests have revealed that the bacteria do belong to the M. tuberculosis complex). In the case of individuals with a very high risk of tuberculosis (e.g. severely immunocompromised patients, neonates) coming into contact with a patient with tuberculosis which has not been Community contact e.g. at school or sports club 6 Significant infection transmission: when proved that more than 1 person has been infected in casual contact group bacteriologically confirmed, indications to a further diagnosis may be considered individually. According to the European consensus, in the case of suspected tuberculosis with a negative sputum smear (and when the culture results have not yet arrived), the presence of a cavity in the chest radiography is an indication to pursue the source's contacts investigation (particularly children < 5 years of age or other high-risk individuals with conditions listed in Table 1 ).
An overview of organization and timing of tuberculosis contact investigations is presented in Table 2 .
Urgent examinations
Children with an increased risk of developing tuberculosis (Table 1) who have come into contact with an index case should be examined first as soon as possible.
This group should preferably undergo both TST and IGRA (if available) as well as a chest radiography. Children with clinical or radiological signs suggestive of tuberculosis should undergo bacteriological tests.
When conducting TST, the site of tuberculin injection must be documented in the patient's records (the first TST should be performed on the inner aspect of the left mid-forearm; so-called first field).
If TST or IGRA are positive, but there are no clinical or radiological signs, LTBI should be identified and the prophylactic treatment started.
Indications for a chest radiography in tuberculosis contacts are listed in Table 3 .
When in doubts about the results of the chest radiography (e.g. suspicion of lung hilar lymph nodes enlargement), contrast-enhanced computed tomography of the chest should be conducted.
When TST and IGRA are negative and there are no clinical or radiological signs in children with a high risk of developing tuberculosis (< 5 years of age, HIV-positive, receiving immunosuppressive treatment), preventive treatment with INH should be initiated.
The remaining children from the close contact group may also be optionally tested urgently. This is even more justified with confirmed transmission 
Tests after an 8-week window
Eight weeks after the last contact with an infectious individual, children previously examined urgently are re-examined, and all other contact children undergo tests.
Children with a high risk of developing tuberculosis undergo repeated TST, IGRA and a chest radiography.
When conducting a repeated tuberculin skin test within a short period of time, one must remember about changing the site of tuberculin injection (the second field: the inner aspect of the right mid-forearm) so as to reduce the risk of a booster effect, which results in an increased skin reaction. If there are radiological abnormalities or clinical signs, bacteriological tests should be conducted.
In children > 6 months of age and < 5 years of age treated preventively with INH, the treatment can be discontinued once the repeated TST and IGRA are negative and there are no clinical/ /radiological signs of the disease.
In children < 6 months of age, HIV-infected or severely immunosuppressed, the preventive treatment with INH should be continued for 6 months even when TST and IGRA are negative.
TST or IGRA, and optionally also a chest radiography, should be conducted in children > 5 years of age without additional risk factors of tuberculosis. If there are radiological abnormalities or clinical signs, bacteriological tests must be ordered.
If TST or IGRA are positive but there are no clinical or radiological signs of tuberculosis, LTBI should be identified and preventive treatment started (according to regimens presented above).
The criteria for interpretation of a positive TST in investigated tuberculosis contacts, as provided in the European consensus, are shown in Table 4 .
As for pulmonary tuberculosis contacts in the school settings, screening should start with high-risk individuals and those who have had the closest and the longest contact with the patient (e.g. class mates, so-called "first circle"). If the infection transmission is confirmed in the first circle, diagnostic tests should also be conducted in occasional contacts ("second circle").
